OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone305-575-4100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$990.30 million
Profitability
Miscellaneous
Employees5,690
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Opko Health (NASDAQ:OPK) Frequently Asked Questions
What is Opko Health's stock symbol?
Opko Health trades on the NASDAQ under the ticker symbol "OPK."
How were Opko Health's earnings last quarter?
Opko Health Inc. (NASDAQ:OPK) released its quarterly earnings results on Wednesday, August, 7th. The biotechnology company reported ($0.10) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.01. The biotechnology company earned $226.40 million during the quarter, compared to analyst estimates of $225.07 million. Opko Health had a negative net margin of 26.55% and a negative return on equity of 12.17%. The business's revenue for the quarter was down 14.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.01) EPS. View Opko Health's Earnings History.
When is Opko Health's next earnings date?
What price target have analysts set for OPK?
1 brokers have issued 12-month target prices for Opko Health's stock. Their forecasts range from $4.00 to $4.00. On average, they expect Opko Health's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 92.3% from the stock's current price. View Analyst Price Targets for Opko Health.
What is the consensus analysts' recommendation for Opko Health?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opko Health.
What are Wall Street analysts saying about Opko Health stock?
Here are some recent quotes from research analysts about Opko Health stock:
- 1. According to Zacks Investment Research, "OPKO Health has gained significantly from RAYALDEE contribution in recent times. Further, OPKO Health’s utilization of the 4Kscore remains strong, with nearly 18,800 tests registered in the second quarter. These apart, the company’s clinical development programs look promising with a robust pipeline of candidates. Several metabolic and endocrinology programs that are underway should provide OPKO Health a competitive advantage. However, the company’s gross margin is under pressure at the moment. Moreover, the company faces cutthroat competition in the MedTech space. Sluggishness in the Services revenue segment remains a concern. OPKO Health underperformed its industry in a year’s time. With respect to quarterly results, OPKO Health exited the second quarter on a strong note." (9/16/2019)
- 2. Barrington Research analysts commented, "We continue to rate OPK shares an OUTPERFORM and our price target remains $4. That said, if the company were to receive a strong data readout from its Phase III trial for hGH‐CTP within the next few months, we suspect that shares would rally meaningfully from current levels and that investor sentiment could swing positive for the first time in over four years. We arrive at our price target via a DCF methodology. It is important to note that the company still has many “shots on goal” within its current commercial portfolio and product development pipeline." (9/12/2019)
Has Opko Health been receiving favorable news coverage?
Media stories about OPK stock have trended negative on Monday, according to InfoTrie. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Opko Health earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Opko Health.
Who are some of Opko Health's key competitors?
Some companies that are related to Opko Health include The Medicines (MDCO), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), Evotec (EVTCY), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), Reata Pharmaceuticals (RETA), Taro Pharmaceutical Industries (TARO), Allakos (ALLK), Alkermes (ALKS) and Global Blood Therapeutics (GBT).
What other stocks do shareholders of Opko Health own?
Who are Opko Health's key executives?
Opko Health's management team includes the folowing people:
- Dr. Phillip Frost, Chairman & CEO (Age 83)
- Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & CTO (Age 72)
- Mr. Adam E. Logal, Sr. VP, CFO, Chief Accounting Officer & Treasurer (Age 41)
- Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 59)
- Ms. Kate Inman, Gen. Counsel & Sec. (Age 46)
Who are Opko Health's major shareholders?
Opko Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include RK Asset Management LLC (0.20%). Company insiders that own Opko Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Institutional Ownership Trends for Opko Health.
Which major investors are buying Opko Health stock?
OPK stock was purchased by a variety of institutional investors in the last quarter, including RK Asset Management LLC. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Insider Buying and Selling for Opko Health.
How do I buy shares of Opko Health?
Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Opko Health's stock price today?
One share of OPK stock can currently be purchased for approximately $2.08.
How big of a company is Opko Health?
Opko Health has a market capitalization of $1.28 billion and generates $990.30 million in revenue each year. The biotechnology company earns $-153,040,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Opko Health employs 5,690 workers across the globe.View Additional Information About Opko Health.
What is Opko Health's official website?
How can I contact Opko Health?
Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]
MarketBeat Community Rating for Opko Health (NASDAQ OPK)
MarketBeat's community ratings are surveys of what our community members think about Opko Health and other stocks. Vote "Outperform" if you believe OPK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPK will underperform the S&P 500 over the long term. You may vote once every thirty days.
